Skip to content
Menu

Medexus Pharmaceuticals Inc. MDP.TO

Full chart Compare
Set alert

Price alert · MDP.TO

All alert types
5.43 CAD -0.26 (-4.57%)

As ofNov 13, 2026, 4:00 PM EST

5.37 Day range 5.69
2.51 52-week range 5.72
YTD
+86.60%
1 year
+101.86%
Market cap
170.64M
Revenue (ttm)
104.76M
Profit margin
2.19%
EPS (ttm)
-0.10
Shares out
24.65M
Forward P/E
-152.50
YTD return
+86.60%
1-year return
+101.86%
Volume
59.15K
Avg volume
39.18K
Open
5.69
Previous close
5.69
Day's range
5.37 – 5.69
52-week range
2.51 – 5.72
Beta
1.95

 

No chart data for this range yet.

Key statistics

Enterprise value
105.52M
PEG ratio
0.00
Price / sales
0.72
Price / book
2.30
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-13.30%
Free cash flow
9.21M
Total cash
6.97M
Total debt
42.97M
Return on equity
8.43%
Short % of float
0.00%
50-day average
2.53
200-day average
2.14

About Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Canada
Website
medexus.com

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on MDP.TO — it syncs with the Stock Master app.

Institution ownership

MDP.TO institution ownership
Holder% heldSharesValueReported
Bard Financial Services, Inc.0.04%10,00030.50KJun 29, 2023

Fund ownership

MDP.TO fund ownership
Holder% heldSharesValueReported
Perritt Microcap Opportunities Fund0.53%130,100396.80KSep 29, 2024